Get the Stockscreener App
25.93
0.93%
0.24
After Hours:
25.93
Smith Nephew Plc Adr stock is traded at $25.93, with a volume of 691.10K.
It is up +0.93% in the last 24 hours and down -10.68% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$25.69
Open:
$25.95
24h Volume:
691.10K
Relative Volume:
0.84
Market Cap:
$11.40B
Revenue:
$5.64B
Net Income/Loss:
$305.00M
P/E Ratio:
37.15
EPS:
0.698
Net Cash Flow:
-
1W Performance:
+3.51%
1M Performance:
-10.68%
6M Performance:
-11.65%
1Y Performance:
+8.40%
1-Day Range:
$25.89
$26.18
1-Week Range:
$25.36
$26.32
52-Week Range:
$23.69
$31.72
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
25.93 | 11.40B | 5.64B | 305.00M | 0 | 0.698 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
SNN (Smith & Nephew plc ADR) may reap gains as insiders became active recently - Knox Daily
Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - GlobeNewswire Inc.
Goldman Downgrades Riskified Ltd (RSKD) to a Sell from a Neutral - Knox Daily
Smith+Nephew to announce 2024 full year results February 25 - Investing.com
Smith+Nephew appoints new Non-Executive Director - Investing.com
Endoprosthesis Market Size to Surpass USD 60.39 Billion by 2032 at a CAGR of 9.86% - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Smith & Nephew Earnings: Quarterly Sales Suggest China Weakness Into 2025 - Morningstar
Smith & Nephew Sees Challenges in China Market - Morningstar
Smith+Nephew, JointVue partner on ultrasound-based surgical planning for surgical robotics - Mass Device
Smith+Nephew launches new Legion knee system - Mass Device
South Korea Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
The Best Healthcare Stocks to Buy - Morningstar
Smith & Nephew Aligns Director Fees with Shares - TipRanks
China Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Japan Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Smith+Nephew announces first Catalystem hip system procedures - Mass Device
Smith+Nephew launches Total Ankle patient-matched guides - Mass Device
Saudi Arabia Antimicrobial Wound Care Dressings Market Size & Outlook, 2030 - Grand View Research
InfuSystem, Smith+Nephew ink wound therapy distro deal - Mass Device
Smith+Nephew shares jump on strong H1 results and reaffirmed guidance - Investing.com UK
Smith+Nephew wins FDA nod for hip system compatible with Cori surgical robot - Mass Device
Europe First Aid Market Size & Outlook, 2023-2030 - Grand View Research
Smith & Nephew stock gains on Cevian stake (NYSE:SNN) - Seeking Alpha
Smith+Nephew launches pre-op planning tech for surgical robotics - Mass Device
Healthcare Sector - Morningstar
Here’s Why You Should Invest in Smith & Nephew plc (SNN) - Yahoo Finance
Smith+Nephew rolls out new chronic wound treatment tech - Mass Device
7 Robotic Surgery Stocks to Buy for the Future of Healthcare - Yahoo Finance
Smith+Nephew sales are up 7% as 12-point plan progresses - Mass Device
Smith+Nephew unveils expanded sports medicine portfolio - Mass Device
Study backs Smith+Nephew Regeneten bioinductive rotator cuff implant - Mass Device
Validea Detailed Fundamental AnalysisSNN - Nasdaq
Smith+Nephew launches hip arthroplasty system in India - Mass Device
Smith+Nephew unveils handheld digital tensioning device for robotic knee surgery - Mass Device
Zimmer Biomet Holdings Inc. stock falls Thursday, underperforms market - MarketWatch
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):